^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BBT-176

    i
    Other names: BBT-176
    Company:
    Bridge Biotherap
    Drug class:
    EGFR inhibitor, Tyrosine kinase inhibitor
    Related drugs:
    1m
    What the future holds: BBT-176, beyond third-generation EGFR tyrosine kinase inhibitors. (PubMed, Transl Lung Cancer Res)
    No abstract available
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Tagrisso (osimertinib) • BBT-176
    5ms
    Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment (clinicaltrials.gov)
    P1/2, N=45, Terminated, Bridge Biotherapeutics, Inc. | Trial completion date: Jun 2024 --> Nov 2023 | Active, not recruiting --> Terminated; Sponsor's decision considering the changing treatment landscape for NSCLC
    Trial completion date • Trial termination
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
    |
    BBT-176
    9ms
    BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. (PubMed, Clin Cancer Res)
    BBT-176 is a fourth-generation EGFR inhibitor showing promising preclinical activity against NSCLC resistant to current EGFR TKIs.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR C797S
    |
    Erbitux (cetuximab) • Tagrisso (osimertinib) • BBT-176
    over1year
    Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment (clinicaltrials.gov)
    P1/2, N=168, Recruiting, Bridge Biotherapeutics, Inc. | N=90 --> 168
    Enrollment change • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
    |
    BBT-176
    2years
    Identification of next-generation EGFR degraders to treat non-small cell lung cancer (NSCLC) patients (AACR 2022)
    A PK study of C-4383 in rats showed good exposure with moderate CL when administered intravenously (CL = 8.51 mL/min/kg, AUC = 5911 ng•h/mL).In summary, we identified heterobifunctional degraders using a 4th generation EGFR inhibitor, BBT-176, that are active in EGFR mutant NSCLC cells harboring single or C797S-containing multiple mutations. We are currently making our efforts on the improvement of physicochemical properties of EGFR mutant targeted heterobifunctional compounds.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR wild-type • EGFR C797S • EGFR H1975
    |
    BBT-176
    3years
    Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Bridge Biotherapeutics, Inc.
    Clinical • New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
    |
    Erbitux (cetuximab) • BBT-176